文献速递膀胱癌与上尿路尿路上皮癌

FGFR3、TERT 和 OTX1 作为尿液生物标志物组合在大型前瞻性多中心研究中用于膀胱癌患者监测

FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
PubMed 文献 · J Urol · 2016-12-31

这项国际多中心前瞻性研究纳入 977 例原发性非肌层浸润性膀胱癌患者,在随访膀胱镜检查前收集 2496 份尿样,评估 FGFR3、TERT 和 OTX1 尿液标志物组合检测复发及预测未来复发的价值。结果显示该组合对低级别复发检测敏感性为 57%,对 pT1 或肌层浸润性复发敏感性为 83%,膀胱镜阴性但尿检阳性者后续复发更常见(58% vs 36%,p<0.001)。

要点

  • 尿液标志物组合对低级别非肌层浸润性膀胱癌复发检测敏感性为 57%。
  • 对 pT1 或肌层浸润性复发的检测敏感性为 83%。
  • 膀胱镜阴性而尿检阳性者后续复发率 58%,高于尿检阴性者的 36%(p<0.001)。

核心结论

  • 原发性非肌层浸润性膀胱癌患者的复发可通过尿液标志物组合检测发现。
  • 该研究支持尿液分析作为低级别肿瘤患者的替代诊断工具,并有助于更早识别高级别肿瘤。

研究设计与样本

  • 国际多中心前瞻性研究,纳入 977 例原发性非肌层浸润性膀胱癌患者,在常规随访膀胱镜检查前共收集 2496 份尿样。
  • 采用 FGFR3、TERT 和 OTX1 尿液标志物组合,估计检测同期复发的敏感性,并用 Kaplan-Meier 曲线估计尿检后膀胱镜阴性者未来复发情况。

主要发现

  • 该组合对原发性低级别非肌层浸润性膀胱癌复发的检测敏感性为 57%。
  • 对 pT1 或肌层浸润性膀胱癌复发的检测敏感性为 83%。
  • 2% 的病例进展为肌层浸润性膀胱癌。
  • 原发性高级别疾病患者的复发检测敏感性为 72%,其中 7% 进展为肌层浸润性膀胱癌。
  • 膀胱镜未发现同期肿瘤时,尿检阳性者后续复发率 58%,高于尿检阴性者的 36%(p<0.001)。

关键数值与推荐

  • 低级别非肌层浸润性膀胱癌复发检测敏感性 57%。
  • pT1 或肌层浸润性膀胱癌复发检测敏感性 83%。
  • 高级别疾病复发检测敏感性 72%,其中 7% 进展为肌层浸润性膀胱癌。
  • 膀胱镜阴性时,尿检阳性者后续复发 58% vs 尿检阴性者 36%(p<0.001)。
  • 高级别复发在尿检阳性且膀胱镜阴性后 1 年内被识别。

临床怎么用

  • 作者认为该研究支持尿液分析作为低级别肿瘤患者的替代诊断工具,并作为更早识别高级别肿瘤的手段。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with nonmuscle invasive bladder cancer are followed with frequent cystoscopies. In this study FGFR3, TERT and OTX1 were investigated as a diagnostic urinary marker combination during followup of patients with primary nonmuscle invasive bladder cancer. MATERIALS AND METHODS: In this international, multicenter, prospective study 977 patients with nonmuscle invasive bladder cancer were included. A total of 2,496 urine samples were collected prior to cystoscopy during regular visits. Sensitivity was estimated to detect concomitant recurrences. Kaplan-Meier curves were used to estimate the development of future recurrences after urinalysis and a negative cystoscopy. RESULTS: Sensitivity of the assay combination for recurrence detection was 57% in patients with primary low grade, nonmuscle invasive bladder cancer. However, sensitivity was 83% for recurrences that were pT1 or muscle invasive bladder cancer. Of the cases 2% progressed to muscle invasive bladder cancer. Sensitivity for recurrence detection in patients with primary high grade disease was 72% and 7% of them had progression to muscle invasive bladder cancer. When no concomitant tumor was found by cystoscopy, positive urine samples were more frequently followed by a recurrence over time compared to a negative urine sample (58% vs 36%, p <0.001). High stage recurrences were identified within 1 year after a positive urine test and a negative cystoscopy. CONCLUSIONS: Recurrences in patients with primary nonmuscle invasive bladder cancer can be detected by a combination of urine assays. This study supports the value of urinalysis as an alternative diagnostic tool in patients presenting with low grade tumors and as a means to identify high stage tumors earlier.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Beukers W, van der Keur KA, Kandimalla R, et al. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study. J Urol. 2016. PMID: 28049011. doi:10.1016/j.juro.2016.12.096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。